The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia
Open accessAbstract
Markers of the kynurenine pathway were studied in postmortem frontal cortex obtained from individuals with schizophrenia and controls. Quantitative endpoint RT-PCR was used to measure mRNA transcripts. Of the two enzymes capable of catalyzing the first step in the pathway, tryptophan 2,3-dioxygenase (TDO2) and indoleamine dioxygenase (IDO), the concentration of mRNA for TDO2 was found to be elevated 1.6-fold in the schizophrenia group (P = 0.03), whereas the concentration of the mRNA for IDO was not significantly different between the schizophrenia and control groups. Immunohistochemistry showed an increased density of TDO2-immunopositive astroglial cells in the white matter of patients with schizophrenia (P = 0.04). Neurons and vessels were also immunopositive for TDO2, but there were no significant differences in labeling of these structures between the two groups. These results add to the evidence that kynurenine pathway changes might be involved in the pathogenesis of schizophrenia and the schizophrenia-like psychoses of other disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of MRI findings in schizophrenia
Shenton, M. E., Dickey, C. C., Frumin, M., & McCarley, R. W. (2001) · Schizophrenia Research · doi:10.1016/s0920-9964(01)00163-3 · Cited by 2,346
Prevalence of smoking among psychiatric outpatients
(1986) · American Journal of Psychiatry · doi:10.1176/ajp.143.8.993 · Cited by 1,058
At Issue: Schizophrenia and Rheumatoid Arthritis: The Negative Association Revisited
Oken, R. J., & Schulzer, M. (1999) · Schizophrenia Bulletin · doi:10.1093/oxfordjournals.schbul.a033407 · Cited by 129
Cited by
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
Opitz, C. A., Litzenburger, U. M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., et al. (2011) · Nature · doi:10.1038/nature10491 · Cited by 1,898
Self-citationKynurenines in the mammalian brain: when physiology meets pathology
Schwarcz, R., Bruno, J. P., Muchowski, P. J., & Wu, H.-Q. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3257 · Cited by 1,530
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
Quinolinic acid, the inescapable neurotoxin
Guillemin, G. J. (2012) · The FEBS Journal · doi:10.1111/j.1742-4658.2012.08485.x · Cited by 595
Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
Pilotte, L., Larrieu, P., Stroobant, V., Colau, D., Dolušić, E., Frédérick, R., De Plaen, E., Uyttenhove, C., Wouters, J., Masereel, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113873109 · Cited by 572
Tryptophan metabolism, from nutrition to potential therapeutic applications
Le Floc’h, N., Otten, W., & Merlot, E. (2011) · Amino Acids · doi:10.1007/s00726-010-0752-7 · Cited by 561
Kynurenine pathway in major depression: Evidence of impaired neuroprotection
Myint, A.-M., Kim, Y. K., Verkerk, R., Scharpé, S., Steinbusch, H., & Leonard, B. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.07.013 · Cited by 527
Tryptophan metabolism in the central nervous system: medical implications
Ruddick, J. P., Evans, A. K., Nutt, D. J., Lightman, S. L., Rook, G. A. W., & Lowry, C. A. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406000068 · Cited by 519
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
Lovelace, M. D., Varney, B., Sundaram, G., Lennon, M. J., Lim, C. K., Jacobs, K., Guillemin, G. J., & Brew, B. J. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.024 · Cited by 393
Increased Levels of Kynurenine and Kynurenic Acid in the CSF of Patients With Schizophrenia
Linderholm, K. R., Skogh, E., Olsson, S. K., Dahl, M.-L., Holtze, M., Engberg, G., Samuelsson, M., & Erhardt, S. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq086 · Cited by 325
Characterization of the Kynurenine Pathway in Human Neurons
Guillemin, G. J., Cullen, K. M., Lim, C. K., Smythe, G. A., Garner, B., Kapoor, V., Takikawa, O., & Brew, B. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4101-07.2007 · Cited by 324
The therapeutic potential of targeting tryptophan catabolism in cancer
Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300
Tryptophan in health and disease
(2020) · Advances in Clinical Chemistry · doi:10.1016/bs.acc.2019.08.005 · Cited by 294
The Role of Immune System in Schizophrenia
Muller, N., & J. Schwarz, M. (2010) · Current Immunology Reviews · doi:10.2174/157339510791823673 · Cited by 291
Spiteri, E., Konopka, G., Coppola, G., Bomar, J., Oldham, M., Ou, J., Vernes, S. C., Fisher, S. E., Ren, B., & Geschwind, D. H. (2007) · The American Journal of Human Genetics · doi:10.1086/522237 · Cited by 285
The kynurenine pathway in schizophrenia and bipolar disorder
Erhardt, S., Schwieler, L., Imbeault, S., & Engberg, G. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.020 · Cited by 255
Impaired Kynurenine Pathway Metabolism in The Prefrontal Cortex of Individuals With Schizophrenia
Sathyasaikumar, K. V., Stachowski, E. K., Wonodi, I., Roberts, R. C., Rassoulpour, A., McMahon, R. P., & Schwarcz, R. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbq112 · Cited by 253
Network beyond IDO in psychiatric disorders: Revisiting neurodegeneration hypothesis
Myint, A.-M., & Kim, Y.-K. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.08.008 · Cited by 230
Inflammation-induced depression: Its pathophysiology and therapeutic implications
Jeon, S. W., & Kim, Y.-K. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.10.016 · Cited by 134
Effects of inflammation on the kynurenine pathway in schizophrenia—a systematic review
Pedraz-Petrozzi, B., Elyamany, O., Rummel, C., & Mulert, C. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1721-z · Cited by 119
Kynurenine pathway in psychosis: evidence of increased tryptophan degradation
Barry, S., Clarke, G., Scully, P., & Dinan, T. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108089583 · Cited by 96
Pathobiological targets of depression
Chopra, K., Kumar, B., & Kuhad, A. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.553603 · Cited by 76
Tryptophan Metabolism and Immunogenetics in Major Depression: A Role for Interferon-γ Gene
Myint, A. M., Bondy, B., Baghai, T. C., Eser, D., Nothdurfter, C., Schüle, C., Zill, P., Müller, N., Rupprecht, R., & Schwarz, M. J. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2013.04.003 · Cited by 74
“TDO2 immunoreactivity was demonstrated in the frontal cortex of the schizophrenic brain (Miller et al., 2004).”
BackgroundGos, T., Myint, A.-M., Schiltz, K., Meyer-Lotz, G., Dobrowolny, H., Busse, S., Müller, U. J., Mawrin, C., Bernstein, H.-G., Bogerts, B., et al. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.012 · Cited by 49
Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders
Debnath, M., Doyle, K., Langan, C., McDonald, C., Leonard, B., & Cannon, D. (2011) · Translational Neuroscience · doi:10.2478/s13380-011-0019-0 · Cited by 28
“This has been confirmed by Miller et al. (2004) [196] showing over-expression of TDO in post-mortem brain samples from patients with SZ.”
Background
Metadata
- Authors
- Miller, C. L., Llenos, I. C., Dulay, J. R., Barillo, M. M., Yolken, R. H., & Weis, S.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 15
- Issue
- 3
- Pages
- 618-629
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2085301448
- Cited by
- 233
- References
- 3
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.